SCHEMBL5659956

SCHEMBL5659956

O=C(NCc1ccc(OC(F)(F)F)cc1)Nc1cc(C(F)(F)F)cc2cnccc12

nearest known ligand 0.74

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 17/20 0.74
NAMPT P43490 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658779 0.90 TRPV1 (0.77) TRPV1NAMPT
SCHEMBL4020314 0.85 TRPV1 (1.00) TRPV1
SCHEMBL5657388 0.83 TRPV1 (0.75) TRPV1NAMPT
SCHEMBL5661863 0.82 TRPV1 (0.68) TRPV1NAMPT
SCHEMBL5659814 0.81 TRPV1 (0.72) TRPV1NAMPT
SCHEMBL5657813 0.79 TRPV1 (0.85) TRPV1NAMPT
SCHEMBL5658881 0.79 IMPDH2 (0.70) TRPV1NAMPT
SCHEMBL5659970 0.78 TRPV1 (0.70) TRPV1NAMPT
SCHEMBL29385974 0.77 TRPV1 (1.00) TRPV1
SCHEMBL2730561 0.77 TRPV1 (1.00) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285563-B2 Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain MERCK SHARP & DOHME LTD. (GB) 2007-10-23 US disclosed
US-20050107388-A1 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain MERCK SHARP & DOHME LTD. (GB) 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107388-A1 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain ARRB1, OPRL1, CNR1 TRPV1 37/4885NAMPT 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.